NCT01316107View on ClinicalTrials.gov

A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

January 15, 2011

Primary Completion Date

October 19, 2012

Study Completion Date

October 19, 2012

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

ipragliflozin

oral

DRUG

nateglinide

oral

Trial Locations (4)

Unknown

Hokkaido

Kantou

Kyushu

Tōhoku

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT01316107 - A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients | Biotech Hunter | Biotech Hunter